TRAW vs VRTX vs IMVT vs GILD vs INVA

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Vertex Pharmaceuticals Incorporated (VRTX) a "Buy" — based on 56 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Vertex Pharmaceuticals Incorporated at 27. 7x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus Vertex Pharmaceuticals Incorporated's 2. 68x — a reasonable growth-adjusted valuation.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -99. 2% for Traws Pharma, Inc. (TRAW). Over 10 years, the gap is even starker: VRTX returned +382. 6% versus TRAW's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Traws Pharma, Inc. 's 1. 60β — meaning TRAW is approximately 1170% more volatile than INVA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -56. 0% for Traws Pharma, Inc.. Over a 3-year CAGR, VRTX leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -241. 9% for Traws Pharma, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -218. 4% for TRAW. At the gross margin level — before operating expenses — TRAW leads at 94. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus Vertex Pharmaceuticals Incorporated's 2. 68x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 22. 2x for Vertex Pharmaceuticals Incorporated — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMVT: 67. 2% to $45. 50.

In this comparison, GILD (2.

4% yield) pays a dividend. TRAW, VRTX, IMVT, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Gilead Sciences, Inc.

(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 4% yield). Traws Pharma, Inc. (TRAW) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GILD: +87. 8%, TRAW: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TRAW is a small-cap quality compounder stock; VRTX is a mid-cap quality compounder stock; IMVT is a small-cap quality compounder stock; GILD is a mid-cap quality compounder stock; INVA is a small-cap high-growth stock. GILD pays a dividend while TRAW, VRTX, IMVT, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.